News stories about Versartis (NASDAQ:VSAR) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Versartis earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.2843204546807 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Healthcare Stock in Focus: Versartis, Inc. (VSAR) (stocksgeeks.com)
- Versartis (VSAR) Rating Lowered to Neutral at Citigroup (americanbankingnews.com)
- Versartis, Inc. (VSAR) Sets 1-Year Low on Apr, 7 at $1.55 (styleonfleek365.com)
- Versartis, Inc. (NASDAQ:VSAR) – An Eye on Data (nasdaqjournal.com)
- Versartis, Inc. (VSAR) Sets 1 Year Low on Apr, 5 (styleonfleek365.com)
Shares of NASDAQ VSAR remained flat at $$1.55 during midday trading on Monday. The company had a trading volume of 439,860 shares, compared to its average volume of 535,577. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.62 and a current ratio of 14.61. Versartis has a 52-week low of $1.50 and a 52-week high of $22.10. The stock has a market capitalization of $55.50, a price-to-earnings ratio of -0.64 and a beta of 2.08.
A number of research firms recently issued reports on VSAR. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st. Canaccord Genuity lowered Versartis from a “buy” rating to a “hold” rating and lowered their price target for the stock from $9.00 to $5.00 in a report on Friday, March 2nd. Finally, ValuEngine raised Versartis from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. Versartis currently has a consensus rating of “Hold” and a consensus target price of $5.13.
In related news, insider Jay Shepard sold 14,446 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $1.80, for a total value of $26,002.80. Following the completion of the sale, the insider now owns 602,298 shares in the company, valued at $1,084,136.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 25,745 shares of company stock valued at $46,124. 10.90% of the stock is owned by insiders.
Versartis Company Profile
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.